2016-03-03T00:00:00.000-05:00
Closed Triple,-0.326801
certain other countries,-0.293068
renal diseases,-0.681033
long-acting muscarinic antagonist,-0.332278
Inc.,0.226584
research efforts,-0.415904
New Employee Equity,0.226584
Theravance Biopharma,0.28018
chronic heart failure,-0.828489
chronic kidney diseases,-0.892984
nebulized treatment,-0.562444
exercise price,0.494866
new employees,0.28018
fluticasone furoate,-0.241277
Incentive Plan,0.226584
Glaxo Group Limited,-0.291972
monthly installments,0.386557
certain difficult-to-treat infections,-0.293068
Inducement Plan,-0.241582
once-daily dual-mechanism antibiotic,0.26503
future payments,-0.291972
GI-targeted pan-JAK inhibitors,-0.500099
selective NEP inhibitors,-0.681033
inflammatory intestinal diseases.,-0.500099
obstructive pulmonary disease,-0.562444
option shares,0.386557
inhibitor program,-0.681033
diabetic nephropathy,-0.892984
equity awards,0.28018
